CYDY Archives - BioTuesdays

Developments

CytoDyn treats first patient in Phase 2 leronlimab basket study

CytoDyn (OTCQB:CYDY) treated the first patient in its Phase 2 basket trial of leronlimab for the treatment of some 22 different types of solid cancer tumors. This Phase 2 trial will enroll 30 patients with CCR5+...

April 15, 2020

Developments

CytoDyn reports positive results from Phase 1b/2 study of leronlimab

CytoDyn (OTCQB:CYDY) reported positive results from its Phase 1b/2 trial of leronlimab in patients with metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Data from the first patient...

January 31, 2020

Feature

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...

September 17, 2019

Developments

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

CytoDyn (OTCQB:CYDY) filed an IND and a Phase 2 clinical trial protocol with the FDA for the treatment of non-alcoholic steatohepatitis (NASH) with its lead drug candidate, leronlimab. Based on published reports of the...

September 4, 2019

Developments

CytoDyn reports interim data from HIV leronlimab monotherapy trial

CytoDyn (OTCQB:CYDY) reported interim data from its dose-escalating trial of leronlimab monotherapy for the treatment of HIV. Leronlimab is humanized monoclonal antibody that targets CCR5, a receptor by which HIV enters...

August 14, 2019

Developments

CytoDyn submits non-clinical portion of BLA for combination HIV therapy

CytoDyn (OTCQB:CYDY) submitted the first of three sections of its BLA to the FDA for leronlimab, for use in combination with highly active antiretroviral therapy for the treatment of HIV. Leronlimab is humanized...

March 20, 2019

Tag - CYDY

CytoDyn treats first patient in Phase 2 leronlimab basket study

CytoDyn reports positive results from Phase 1b/2 study of leronlimab

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

CytoDyn files IND and Phase 2 protocol to treat NASH with leronlimab

CytoDyn reports interim data from HIV leronlimab monotherapy trial

CytoDyn submits non-clinical portion of BLA for combination HIV therapy

General

More